<DOC>
	<DOCNO>NCT01919489</DOCNO>
	<brief_summary>High blood glucose level hospitalize patient diabetes associate increased risk medical complication death . Improved glucose control insulin injection may improve clinical outcome prevent hospital complication . Increasing evidence indicate incretin-based agent safe effective hospital management patient type 2 diabetes ( T2D ) . Liraglutide once-daily human glucagon-like peptide ( GLP-1 ) analogue approve treatment T2D . Liraglutide show low blood glucose , stimulate endogenous insulin secretion , decrease plasma glucagon level , inhibit gastric emptying , reduce food intake body weight improve ß-cell function administer subcutaneously . Liraglutide increase insulin secretion glucose-dependent manner ( i.e. , plasma glucose level elevate ) , result low-risk hypoglycemia use monotherapy . When compare insulin glargine therapy , use GLP-1 result comparable reduction HbA1c level , low rate hypoglycemia less weight gain . No prospective study ; however , compare efficacy safety liraglutide hospital set hospital discharge . The primary objective compare safety efficacy liraglutide ( Victoza® ) versus glargine insulin combination oral anti-diabetic agent ( OADs : metformin , sulfonylurea , nateglinide , repaglinide pioglitazone ) glycemic control 26 week treatment medicine patient T2D hospital discharge .</brief_summary>
	<brief_title>Liraglutide Hospital Discharge Trial</brief_title>
	<detailed_description>Specific Aim : To determine whether treatment liraglutide ( Victoza® ) result similar glycemic control ( HbA1c 26 week ) low rate hypoglycemic event compare treatment glargine ( Lantus® ) non-surgical patient T2D hospital discharge . Patients poorly control ( HbA1c &gt; 7 % -10 % ) T2D treat diet oral antidiabetic agent ( insulin naïve ) prior admission randomize liraglutide glargine combination OADs hospital discharge .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Males female age 18 80 year discharge hospital admission general medicine service ( nonsurgical nonICU set ) . 2 . Admission HbA1c 7 % 10 % 3 . Patients T2D treat diet alone oral antidiabetic agent monotherapy combination therapy ( exclude GLP1 receptor agonist ) lowdose insulin therapy ( TDD ≤0.4 unit/kg/day ) prior admission . 4 . Subjects hospital admission BG &lt; 400 mg/dL without laboratory evidence diabetic ketoacidosis ( serum bicarbonate &lt; 18 mEq/L positive serum urinary ketone ) . 5 . BMI &gt; 25 Kg/m2 &lt; 45 Kg/m2 1 . Age &lt; 18 &gt; 80 year . 2 . Subjects increase BG concentration , without history diabetes ( stress hyperglycemia ) 3 . Subjects history type 1 diabetes ( suggest BMI &lt; 25 Kg/m2 require insulin therapy history diabetic ketoacidosis hyperosmolar hyperglycemic state , ketonuria ) . 4 . Treatment insulin GLP1 analogs past 3 month prior admission . 5 . Recurrent severe hypoglycemia hypoglycemic unawareness . 6 . Subjects gastrointestinal obstruction , gastroparesis expect require gastrointestinal suction . 7 . History medullary thyroid cancer multiple endocrine neoplasia 8 . Patients acute chronic pancreatitis , pancreatic cancer gallbladder disease . 9 . Patients clinically significant hepatic disease ( cirrhosis , jaundice , endstage liver disease , portal hypertension ) elevate ALT AST &gt; 3 time upper limit normal , significantly impaired renal function ( GFR &lt; 30 ml/min ) . 10 . Treatment oral injectable corticosteroid , parenteral nutrition immunosuppressive treatment . 11 . Mental condition render subject unable understand nature , scope , possible consequence study . 12 . Female subject pregnant breast feeding time enrollment study . 13 . Females childbearing potential use adequate contraceptive method ( require local law practice ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Incretins</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Glargine</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>basal insulin</keyword>
	<keyword>hospital discharge</keyword>
	<keyword>inpatient diabetes</keyword>
</DOC>